My5FU

Outcomes for patients receiving optimal exposure to imatinib are similar to other TKI

Sub-optimal responses and treatment failures with imatinib may be address4ed by exposure evaluation and dosing optimization.12,13

  • Help avoid sub-optimal therapeutic response

  • Help identify potential non-adherence to therapy

  • Help reduce toxicity in patients receiving too much drug, potentially improving the patient’s quality of life

 

Saladax Resources

5Fu FU FU FU

5Fu FU FU FU

Poster presented at Asco

 
stuff

stuff

stuff

 

Publications of Interest

Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage

Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage

The use of drug combinations has transformed met- astatic colorectal cancer treatment, with fluorouracil (FU) remaining the cornerstone of this treatment.1-6 Although initial intensification of FU, in combina- tion with other drugs, is the widely used approach from the inception, questions arise  as to when these regimens should be introduced, whether initially or as soon as a tumor escape is suspected.

 
ersonalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5eFluorouracil-Based Chemotherapy Regimens

ersonalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5eFluorouracil-Based Chemotherapy Regimens

5-Fluorouracil (5-FU) has been a mainstay of colorectal cancer (CRC) chemotherapy for more than 50 years. There have been efforts to personalize CRC therapy by identifying genetic factors that determine response, toxicity, and resistance to 5-FU.

 
Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6

Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6

In the treatment of cancer patients with cytotoxic drugs, a prime consideration is improving the therapy outcome by in- creasing efficacy while maintaining an acceptable toxicity pro- file.

 

 
A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy

A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy

5-Fluorouracil (5-FU) has remained the backbone of colorectal cancer (CRC) therapy for more than 50 years [1–5]. Compared with bolus dosing, continuous intravenous infusion of 5-FU has allowed for higher tolerable doses to be administered to patients, thereby enhancing clinical effectiveness 

 
 
Current Chemo Dosing Practices

Current Chemo Dosing Practices

 

Text For Button

 

Text For Button